drugset / Trial / NCT04332107
Azithromycin for COVID-19 Treatment in Outpatients Nationwide
Phase 3
Terminated
263 enrolled
Thomas M. Lietman
Bill and Melinda Gates Foundation · collabPfizer · collabStanford University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This individually randomized telemedicine-based trial aims to evaluate the efficacy of a single dose of azithromycin for prevention of progression of COVID-19 in patients with a recent positive SARS-CoV-2 test who are not currently hospitalized.
Timeline
- Start
- 2020-05-22
- Primary completion
- 2021-03-16
- Completion
- 2021-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azithromycin | Small molecule | 1.2 g | Oral |